Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Jungnang-Gu, Korea, Republic of Clinical Trials

A listing of Jungnang-Gu, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (721) clinical trials

A Multicenter Randomized 52 Week Treatment Double-blind Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma

The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 g and QMF149 150/320 g via Concept1) over two respective MF doses (MF 400 g and MF 800 g via Twisthaler (total daily dose)) in poorly controlled asthmatic patients as ...

Phase

0.56 miles

Learn More »

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma

Phase

1.14 miles

Learn More »

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

This is a prospective, multicenter, non-interventional study to test the safety and effectiveness of MabThera administered subcutaneously in participants with NHL or CLL. The length of study is expected to be 6 years.

Phase N/A

1.14 miles

Learn More »

Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Essential Hypertension Patients

Levacalm Tab. was approved in Jul 2013 by MFDS in South Korea. Levacalm Tab. is combination drug of Valsartan as an angiotensin II receptor blocker and Lercanidipine as a Calcium channel blocker. It is a new drug of combination of Valsartan and Lercanidipine. Thus, there's no enough safety data and ...

Phase N/A

1.8 miles

Learn More »

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

Biliary tract cancer is relatively rare disease worldwide among all kinds of solid tumors. However the incidence of biliary tract cancer is relatively higher in Korea compared to the western countries. The prognosis of all biliary tract cancer is poor, that is, the 5-year overall survival rate is 26.7%. The ...

Phase

1.8 miles

Learn More »

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

This is a Phase III, randomized, double blind, dummy controlled safety and efficacy study of ThermoDox plus sRFA compared to sRFA plus dummy infusion using standardized treatment dwell time for solitary HCC lesions 3.0 cm to 7.0 cm. An sRFA treatment for this protocol is defined as the dwell time ...

Phase

1.8 miles

Learn More »

Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)

About 3400 patients derived from a population of Korean patients with acute coronary syndrome receiving percutaneous coronary intervention will be enrolled in the present trial. All patients will receive a loading dose of aspirin (300 mg) and prasugrel (60 mg bolus) will be administered. Sixty-mg-loading dose of prasugrel will be ...

Phase

1.8 miles

Learn More »

Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients

To test the effect of low-dose dexmedetomidine for lowering the incidence of postoperative delirium in liver transplant patients in the ICU. Single center prospective randomized placebo controlled clinical trial 0.1mcg/kg/hr of dexmedetomidine or equivalent amount of saline infusion started after induction of anesthesia for liver transplantation and continued until 48 ...

Phase

1.8 miles

Learn More »

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

There remains an unmet medical need to develop EGFR TKI agents that effectively target both the single activating mutations of del 19 and L858R, and the secondary resistance mutation T790M, while sparing WT EGFR. Drugs active against the resistance mutation will enable molecularly targeted therapy with a more favorable toxicity ...

Phase

1.8 miles

Learn More »

Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer

OBJECTIVES: Primary - Determine the maximum tolerated dose and recommended phase II dose of paclitaxel-loaded polymeric micelle and carboplatin as first-line therapy in patients with advanced ovarian cancer. (Phase I) - Evaluate the efficacy of this regimen, in terms of CA-125 response rate after 6 courses of therapy. (Phase II) ...

Phase

1.8 miles

Learn More »